Actively Recruiting
Thymalfasin and Recombinant Human IL-2 Injections in Treating Lymphocytopenia for Patients With Malignant Hematological Tumors
Led by The First Affiliated Hospital of Xiamen University · Updated on 2024-09-19
50
Participants Needed
1
Research Sites
182 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To evaluate the efficacy and safety of Thymalfasin for injection in combination with Recombinant Human Interleukin-2 Injections in the treatment of lymphocytopenia in patients with malignant hematological tumors
CONDITIONS
Official Title
Thymalfasin and Recombinant Human IL-2 Injections in Treating Lymphocytopenia for Patients With Malignant Hematological Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with histologically confirmed myeloid, B lymphocyte, or plasma cell-derived malignant hematological tumors
- Lymphocyte count 30.8 x 10^9/L or CD4+ T cell count 35 x 10^9/L
- Age 18 years or older
- Expected survival period longer than 3 months
- Estimated creatinine clearance rate 30 mL/min
- AST and ALT levels 3 times the upper limit of normal
- Bilirubin 1.5 times the upper limit of normal
- Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less
- Able to understand and voluntarily provide informed consent
You will not qualify if you...
- Active autoimmune disease
- Presence of malignant T-cell clone
- Chemotherapy for lymphoma within 8 days or chemotherapy for AML within 14 days
- Tumor involvement in bone marrow causing hematopoietic suppression (neutrophils <1.0 x 10^9/L, hemoglobin <70 g/L, platelets <50 x 10^9/L)
- HIV-positive or active hepatitis B or C infection
- Chronic respiratory disease requiring continuous oxygen or significant medical history of kidney, neurological, psychiatric, endocrine, metabolic, immune, liver, or cardiovascular diseases
- Immunosuppressive treatment within the past 5 days
- Psychiatric disorders interfering with participation
- Previous allogeneic hematopoietic stem cell transplantation
- Allergy to Thymalfasin or Interleukin-2
- Any other condition deemed unsuitable by the researcher
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Zhijuan Lin
Xiamen, Fujian, China
Actively Recruiting
Research Team
Z
Zhijuan Lin
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here